Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

101. An evidence-based, point-of-care tool to guide completion of asthma action plans in practice

An evidence-based, point-of-care tool to guide completion of asthma action plans in practice 28461295 2017 05 02 2017 06 11 1399-3003 49 5 2017 May The European respiratory journal Eur. Respir. J. An evidence-based, point-of-care tool to guide completion of asthma action plans in practice. 1602238 10.1183/13993003.02238-2016 Asthma action plans (AAPs) reduce healthcare utilisation, improve quality of life and are recommended across guidelines. However, fewer than 25% of patients receive an AAP (...) , partly due to prescribers' inability to complete "yellow zone" instructions (how to intensify therapy for acute loss of control). We sought to review best evidence to develop a practical, evidence-based tool to facilitate yellow zone guidance in adults.We reviewed recent asthma guidelines and adult studies addressing acute loss of asthma control (January 2010 to March 2016). We developed evidence-based rules for yellow zone therapy and operational guidelines to maximise adherence and minimise

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

102. [Reslizumab (severe eosinophilic asthma) - Benefit assessment according to õ 35a Social Code Book V]

[Reslizumab (severe eosinophilic asthma) - Benefit assessment according to õ 35a Social Code Book V] Reslizumab (Asthma): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-02 [Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V] Reslizumab (Asthma): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-02 [Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Reslizumab (Asthma): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-02. [Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code

Health Technology Assessment (HTA) Database.2017

103. [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough]

[Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough] [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough] [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough] Virgilio S, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Virgilio S, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A. [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 536. 2017 Authors' conclusions Moderate quality evidence suggests that fractional exhaled

Health Technology Assessment (HTA) Database.2017

104. Budesonide-formoterol (Symbicort SMART) - asthma

Budesonide-formoterol (Symbicort SMART) - asthma Published 12 June 2017 Product Update: budesonide/formoterol 100 micrograms/6 micrograms and 200 micrograms/6 micrograms inhalation powder (Symbicort ® SMART ® ) SMC No. (1244/17) AstraZeneca UK Ltd 05 May 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE (...) : following an abbreviated submission budesonide/formoterol (Symbicort ® SMART ® ) is accepted for use within NHS Scotland. Indication under review: the regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting ß 2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” short-acting ß2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting ß2

Scottish Medicines Consortium2017

105. A pharmacy management service for adults with asthma: a cluster randomised controlled trial

A pharmacy management service for adults with asthma: a cluster randomised controlled trial 28472499 2017 05 04 2017 05 04 1460-2229 2017 May 03 Family practice Fam Pract A pharmacy management service for adults with asthma: a cluster randomised controlled trial. 10.1093/fampra/cmx028 Although clinical guidelines are available for the management of asthma, this health condition is still poorly managed in many countries. To assess the effects of a Pharmacy Management Service (PharMS) on asthma (...) control of adult patients. This study comprised of a cluster randomised controlled trial (RCT) that was conducted from April 2014 to July 2015 at four government health clinics. The control participants received usual pharmacy service, while the intervention participants were recruited into the PharMS. Each participant was monitored for 6 months, and the outcome measures included asthma control using the Asthma Control Test (ACT), inhaler technique using a checklist and medication adherence using

EvidenceUpdates2017

106. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. Background Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated (...) with eosinophilia. Methods In a 28-week randomized, controlled trial, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or every 8 weeks [with the first three doses administered every 4 weeks]) versus placebo on the reduction in the oral glucocorticoid dose while asthma control was maintained in adult patients with severe asthma. The primary end point was the percentage change in the oral glucocorticoid dose from baseline to week 28. Annual asthma

NEJM2017

107. KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma.

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. BACKGROUND: Mast cells are present in the airways of patients who have severe asthma despite glucocorticoid treatment; these cells are associated with disease characteristics including poor quality of life and inadequate asthma control. Stem cell factor and its receptor, KIT, are central to mast-cell homeostasis. We conducted a proof-of-principle trial to evaluate the effect of imatinib, a KIT inhibitor, on airway (...) hyperresponsiveness, a physiological marker of severe asthma, as well as on airway mast-cell numbers and activation in patients with severe asthma. METHODS: We conducted a randomized, double-blind, placebo-controlled, 24-week trial of imatinib in patients with poorly controlled severe asthma who had airway hyperresponsiveness despite receiving maximal medical therapy. The primary end point was the change in airway hyperresponsiveness, measured as the concentration of methacholine required to decrease the forced

NEJM2017

108. Do Inhaled Anticholinergic Agents in Addition to ß-Agonists Improve Outcomes in Acute Asthma Exacerbations?

Do Inhaled Anticholinergic Agents in Addition to ß-Agonists Improve Outcomes in Acute Asthma Exacerbations? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2017

109. Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations: A Randomized Controlled Trial

Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations: A Randomized Controlled Trial 28284473 2017 03 12 2017 03 12 1097-6833 2017 Mar 08 The Journal of pediatrics J. Pediatr. Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations: A Randomized Controlled Trial. S0022-3476(17)30230-5 10.1016/j.jpeds.2017.02.032 To evaluate the efficacy of brief, single administration of positive expiratory pressure (PEP) therapy in reducing clinical severity and need (...) for additional second-line therapies and hospitalization in children presenting to the emergency department (ED) with acute asthma. This was a prospective randomized controlled trial of children 2-18 years of age presenting to a tertiary-care academic pediatric ED with moderate-to-severe asthma exacerbations from December 2014 to June 2016. Children who continued to have moderate asthma severity after completion of initial therapies (albuterol/ipratropium bromide and corticosteroids) were randomized

EvidenceUpdates2017

111. What is the best therapy for exercise induced asthma in adults?

What is the best therapy for exercise induced asthma in adults? What is the best therapy for exercise induced asthma in adults? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What is the best therapy for exercise induced asthma in adults? View/ Open Date 2017-03 Format Metadata Abstract What is the best therapy (...) for exercise induced asthma in adults? Evidence-based answer: The answer is unclear. A single dose of either a short- or long-acting beta-agonist improves forced expiratory volume in 1 second (FEV1) (SOR: C, meta-analysis of crossover and cohort studies with disease-oriented outcomes), but long-term regular use of either class of agent may induce tolerance and decrease efficacy in exercise-induced asthma (SOR: C, expert opinion). Montelukast or fish oil appear to decrease bronchodilator use and improve

Evidence Based Practice 2017

112. Asthma education for school staff.

Asthma education for school staff. BACKGROUND: Teachers and school staff should be competent in managing asthma in schools. Demonstrated low levels of asthma knowledge mean that staff may not know how best to protect a child with asthma in their care, or may fail to take appropriate action in the event of a serious attack. Education about asthma could help to improve this knowledge and lead to better asthma outcomes for children. OBJECTIVES: To assess the effectiveness and safety of asthma (...) education programmes for school staff, and to identify content and attributes underpinning them. SEARCH METHODS: We conducted the most recent searches on 29 November 2016. SELECTION CRITERIA: We included randomised controlled trials comparing an intervention to educate school staff about asthma versus a control group. We included studies reported as full text, those published as abstract only and unpublished data. DATA COLLECTION AND ANALYSIS: At least two review authors screened the searches, extracted

Cochrane2017

113. Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma?

Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? Evidencias en pediatría - Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset (...) password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × March 2017. Volume 13. Number 1 Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email Confirm email I accept the journal’s

Evidencias en Pediatría2017

114. Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Published on: March 23, 2017 Project Number (...) : RB1076-000 Product Line: Research Type: Drugs Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of antibiotics for acute asthma exacerbations without clear signs of bacterial infection? What is the cost-effectiveness of antibiotics for acute asthma exacerbations without clear signs of bacterial infection? What are the evidence-based guidelines regarding the use of antibiotics for acute asthma exacerbations? Key Message Three randomized-control trials

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

115. SQ HDM SLIT-tablet for house dust mite allergic asthma

SQ HDM SLIT-tablet for house dust mite allergic asthma SQ HDM SLIT-tablet for house dust mite allergic asthma ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year SQ HDM SLIT-tablet for house dust mite allergic asthma March 2017 Specialty You may also be interested in: Dec 2013 Specialty: Dec 2013 Specialty: Apr 2013 Specialty: Please answer these 2 questions to proceed to your free download Where are you based? England Wales, Scotland, N.Ireland Other country

NIHR Innovation Observatory2017

116. Effect of an Integrated Pest Management Intervention on Asthma Symptoms Among Mouse-Sensitized Children and Adolescents With Asthma: A Randomized Clinical Trial.

Effect of an Integrated Pest Management Intervention on Asthma Symptoms Among Mouse-Sensitized Children and Adolescents With Asthma: A Randomized Clinical Trial. Importance: Professionally delivered integrated pest management (IPM) interventions can reduce home mouse allergen concentrations, but whether they reduce asthma morbidity among mouse-sensitized and exposed children and adolescents is unknown. Objective: To determine the effect of an IPM intervention on asthma morbidity among mouse (...) -sensitized and exposed children and adolescents with asthma. Design, Setting, and Participants: Randomized clinical trial conducted in Baltimore, Maryland, and Boston, Massachusetts. Participants were mouse-sensitized and exposed children and adolescents (aged 5-17 years) with asthma randomized to receive professionally delivered IPM plus pest management education or pest management education alone. Enrollment occurred between May 2010 and August 2014; the final follow-up visit occurred on September 25

JAMA2017

117. Nitric oxide breath analysis for the management of asthma

Nitric oxide breath analysis for the management of asthma Nitric oxide breath analysis for the management of asthma Nitric oxide breath analysis for the management of asthma HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Nitric oxide breath analysis for the management of asthma. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors (...) ' objectives The measurement of nitric oxide (NO) concentration in expired breath has been introduced as an adjunct to or replacement for established clinical and laboratory assessments of asthma control to guide the management of asthma. Measurement of fractional exhaled nitric oxide (FENO) is a noninvasive diagnostic technique. The NO molecules exhaled in breath can be measured using a handheld electrochemical sensor or a large, stationary chemiluminescence gas analyzer. Controversy: NO, which

Health Technology Assessment (HTA) Database.2017

118. Nitric oxide breath analysis for the diagnosis of asthma

Nitric oxide breath analysis for the diagnosis of asthma Nitric oxide breath analysis for the diagnosis of asthma Nitric oxide breath analysis for the diagnosis of asthma HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Nitric oxide breath analysis for the diagnosis of asthma. Lansdale: HAYES, Inc. Directory Publication. 2016 Authors (...) ' objectives The measurement of nitric oxide (NO) concentration in expired breath has been introduced as an adjunct to or replacement for the established clinical and laboratory assessments for the diagnosis of asthma. Measurement of fractional exhaled nitric oxide (FENO) is a noninvasive diagnostic technique. The NO molecules exhaled in breath can be measured using a handheld electrochemical sensor or a large, stationary chemiluminescence gas analyzer. Controversy: NO, which is normally produced

Health Technology Assessment (HTA) Database.2017

119. Australian Asthma Handbook

Australian Asthma Handbook Australian Asthma Handbook | Australian Asthma Handbook Know what you're looking for? Australia's National Guidelines for Asthma Management The Australian Asthma Handbook provides best-practice, evidence-based guidance translated into practical advice for primary care health professionals. The Handbook is proudly published by Australia's lead asthma authority, the National Asthma Council Australia. 1 2 3 1 2 3 1 2 3 Australian Asthma Handbook v1.2 Version 1.2 (...) continues to set the standard for practical, evidence-based advice for primary care chronic disease management. Stay up to date Join our health professional community and stay informed on Handbook updates Disclaimer The Australian Asthma Handbook is the national guidelines for asthma management in primary care. It has been developed for use by Australian health professionals. Use of this website is subject to disclaimers that we encourage you to . © National Asthma Council Australia 2017 site by

Clinical Practice Guidelines Portal2017